A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Fosbretabulin Tromethamine (CA4P) in Combination With Paclitaxel and Carboplatin in Anaplastic Thyroid Carcinoma (FACT2)

Trial Profile

A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Fosbretabulin Tromethamine (CA4P) in Combination With Paclitaxel and Carboplatin in Anaplastic Thyroid Carcinoma (FACT2)

Withdrawn prior to enrolment
Phase of Trial: Phase III

Latest Information Update: 14 Jul 2016

At a glance

  • Drugs Fosbretabulin (Primary) ; Carboplatin; Paclitaxel
  • Indications Thyroid cancer
  • Focus Registrational; Therapeutic Use
  • Acronyms FACT-2
  • Sponsors Mateon Therapeutics
  • Most Recent Events

    • 30 Apr 2014 Status changed from not yet recruiting to withdrawn prior to recruitment as reported by ClinicalTrials.gov record.
    • 26 Feb 2014 Planned initiation date changed from 1 Dec 2012 to 1 Mar 2015 as reported by ClinicalTrials.gov record.
    • 19 Sep 2012 Planned initiation date changed from 1 Jun 2012 to 1 Dec 2012.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top